← Leaderboards
Nunzio Pomara
Nathan S. Kline Institute For Psych Res
$6,896,923
Attributed
$6,896,923
Total exposure
7
Grants
5
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $794.5K · FY2005–25$1M$750K$500K$250K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$6,896,923 · 7
By mechanism
R01$6,853,051 · 3
M01$43,872 · 4
Top collaborators
No co-investigators on record.
Others in their field
Top investigators on “S Disease”
- Lawrence Corey · Fred Hutchinson Cancer Center$643,566,627
- Jeffrey P Krischer · University Of South Florida$588,279,843
- Bambra Strokes · Ppd Development Lp$526,656,217
- Judith S. Currier · University Of California Los Angeles$477,614,997
- David Heimbrook · Leidos Biomedical Research, Inc.$470,438,912
- Joseph J. Eron · Univ Of North Carolina Chapel Hill$389,132,404
Research focus
S DiseaseAlzheimer&AposPlasmaElderlyMajor Depressive DisorderAmyloid Beta-ProteinCognitiveImpaired CognitionCerebrospinal FluidBiological MarkersEtiologyDepressive SymptomsReportingPeptidesResearch PersonnelMagnetic Resonance ImagingLongitudinal StudiesGeriatric Major DepressionLinkLorazepamBloodEvaluationBrainFollow-Up
Grant awards (20)
Depression treatment and Aβ dynamics: A study of Alzheimerâs disease risk$741,212
R01 · FY2025 · AG · contact PI
Depression treatment and Aβ dynamics: A study of Alzheimerâs disease risk$761,833
R01 · FY2024 · AG · contact PI
Depression treatment and Aβ dynamics: A study of Alzheimerâs disease risk$782,446
R01 · FY2023 · AG · contact PI
Depression treatment and Aβ dynamics: A study of Alzheimerâs disease risk$794,492
R01 · FY2022 · AG · contact PI
Depression treatment and Aβ dynamics: A study of Alzheimerâs disease risk$785,139
R01 · FY2021 · AG · contact PI
Plasma and CSF Abeta peptides in late-onset major depression$273,981
R01 · FY2011 · MH · contact PI
Plasma and CSF Abeta peptides in late-onset major depression$301,441
R01 · FY2010 · MH · contact PI
Plasma and CSF Abeta peptides in late-onset major depression$277,293
R01 · FY2009 · MH · contact PI
Plasma and CSF Abeta peptides in late-onset major depression$391,648
R01 · FY2008 · MH · contact PI
PLASMA AND CSF ABETA PEPTIDES IN LATE-ONSET MAJOR DEPRESSION$8,801
M01 · FY2008 · RR · contact PI
Plasma and CSF Abeta peptides in late-onset major depression$375,186
R01 · FY2007 · MH · contact PI
LONGTERM LORAZEPAM USE AND ACUTE TOXICITY IN THE ELDERLY$4,734
M01 · FY2007 · RR · contact PI
LONGTERM LORAZEPAM USE AND ACUTE TOXICITY IN THE ELDERLY$15,431
M01 · FY2006 · RR · contact PI
LONG-TERM LORAZEPAM USE AND ACUTE TOXICITY IN THE AGED$274,524
R01 · FY2005 · MH
LONGTERM LORAZEPAM USE AND ACUTE TOXICITY IN THE ELDERLY$5,252
M01 · FY2005 · RR
LONG-TERM LORAZEPAM USE AND ACUTE TOXICITY IN THE AGED$271,771
R01 · FY2004 · MH
Longterm Lorazepam Use and Acute Toxicity in the Elderly$9,654
M01 · FY2004 · RR
LONG-TERM LORAZEPAM USE AND ACUTE TOXICITY IN THE AGED$269,098
R01 · FY2003 · MH
LONG-TERM LORAZEPAM USE AND ACUTE TOXICITY IN THE AGED$266,503
R01 · FY2002 · MH
LONG-TERM LORAZEPAM USE AND ACUTE TOXICITY IN THE AGED$286,484
R01 · FY2001 · MH